NewLink Genetics, which received poor news from a key drug trial, reported a net loss of $32.4 million, or $1.12 per diluted share, for the second quarter of 2016, the company reported today. That compares with a net loss of $14.1 million, or 49 cents per diluted share, for the same quarter last year. The Ames-based company, which is working on vaccines for cancer and Ebola, said it would reduce its staff to about 130 from 230 and would restructure its operations to focus on its most promising products. The company had $12.3 million in severance and other restructuring expenses in the quarter.